Institut Gustave Roussy; Departement Oncologie Medicale
Villejuif, France
Cancer treatment center in Villejuif
114 Rue Edouard Vaillant, 94805 Villejuif
457 Beds
About Institut Gustave Roussy; Departement Oncologie Medicale
Gustave Roussy is the first leader cancer-research hospital in Europe and ranked among the top 5 best specialized hospitals in the world. It is a centre for high quality patient care, research and teaching. It is highly-known for the treatment of: skin cancers like melanoma, breast cancer, and lung cancer.
There are 457 beds in Institut Gustave Roussy; Departement Oncologie Medicale.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
14
Genentech, Inc.
6
Clinical Trials at Institut Gustave Roussy; Departement Oncologie Medicale
During the past decade, Institut Gustave Roussy; Departement Oncologie Medicale conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 10 clinical trials were completed, i.e. on
average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors
2011-07-11
2020-10-16
Completed
122
An Observational Study of Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer Treated With Herceptin (Trastuzumab) in 1st Line and Without Progression For 3 Years
2011-03-28
2012-11-16
Completed
160
Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy
2012-01-11
2022-08-31
Completed
273
Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer
2012-01-20
2016-03-30
Completed
501
A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma
2012-03-23
2018-01-11
Completed
104
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)
2013-04-03
2025-04-03
Active, not recruiting
1,487
A Dose-Escalation Study of GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
2013-06-21
2016-09-23
Completed
40
A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
2013-08-14
2021-01-26
Completed
153
Clinical Trials Sponsors and Collaborators
In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Gustave Roussy; Departement Oncologie Medicale"
#1 collaborator was "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator, "German Breast Group" with 1 trials as a collaborator and "Institut Jules Bordet/Clinical Trials Support Unit (IJB/CTSU)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were
collaborators in the rest 6 trials.
Clinical Trials Conditions at Institut Gustave Roussy; Departement Oncologie Medicale
According to Clinical.Site data, the most researched conditions in "Institut Gustave Roussy; Departement Oncologie Medicale" are
"Breast Cancer" (3 trials), "Neoplasms" (3 trials), "Non-Small Cell Lung Cancer" (2 trials), "Renal Cell Carcinoma" (2 trials) and "Adenocarcinoma" (1 trials). Many other conditions were trialed in "Institut Gustave Roussy; Departement Oncologie Medicale" in a lesser frequency.
Clinical Trials Intervention Types at Institut Gustave Roussy; Departement Oncologie Medicale
Most popular intervention types in "Institut Gustave Roussy; Departement Oncologie Medicale" are "Drug" (20 trials) and "Other" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (5 trials), "Paclitaxel" (5 trials), "Placebo" (5 trials), "Ipatasertib" (4 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.
Clinical Trials Genders at Institut Gustave Roussy; Departement Oncologie Medicale
The vast majority of trials in "Institut Gustave Roussy; Departement Oncologie Medicale" are
17 trials for "All" genders, 2 trials for "Male" genders and 1 trials for "Female" genders.
Clinical Trials Status at Institut Gustave Roussy; Departement Oncologie Medicale
Currently, there are NaN active trials in "Institut Gustave Roussy; Departement Oncologie Medicale".
undefined are not yet recruiting,
2 are recruiting,
3 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 15 completed trials in Institut Gustave Roussy; Departement Oncologie Medicale,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Institut Gustave Roussy; Departement Oncologie Medicale, 6 "Phase 1"
clinical trials were conducted, 7 "Phase 2" clinical
trials and 7 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".